These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39039774)

  • 1. Toxicity profile of high-dose methotrexate in young children with central nervous system tumors.
    Chavana AN; Taylor ZL; DeGroote N; Lindsay HB; Sauer HE; Mason EJ; Schafer ES; Miller TP; Castellino SM; Pommert L; O'Brien MM; Ramsey LB; Bernhardt MB; Brown AL
    Pediatr Blood Cancer; 2024 Oct; 71(10):e31213. PubMed ID: 39039774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma.
    Bernard S; Hachon L; Diasonama JF; Madaoui C; Aguinaga L; Miekoutima E; Moatti H; Perrial E; Madelaine I; Brice P; Thieblemont C
    Ann Hematol; 2021 Apr; 100(4):979-986. PubMed ID: 33608849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections.
    Wright KD; Panetta JC; Onar-Thomas A; Reddick WE; Patay Z; Qaddoumi I; Broniscer A; Robinson G; Boop FA; Klimo P; Ward D; Gajjar A; Stewart CF
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):27-35. PubMed ID: 25342291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
    Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
    Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia.
    Sari NM; Rakhmilla LE; Bashari MH; Zazuli Z; Suryawan N; Susanah S; Reniarti L; Raspati H; Supriyadi E; Kaspers GJL; Idjradinata P
    Asian Pac J Cancer Prev; 2021 Jul; 22(7):2025-2031. PubMed ID: 34319023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?
    Khan RB; Shi W; Thaler HT; DeAngelis LM; Abrey LE
    J Neurooncol; 2002 Jun; 58(2):175-8. PubMed ID: 12164690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solitary serum methotrexate level 36 hours post high-dose methotrexate: A safe, efficacious, and cost-effective strategy to monitor methotrexate toxicities in childhood leukemia in resource-limited centers.
    Khera S; Kapoor R; Pramanik SK
    Pediatr Blood Cancer; 2020 Jul; 67(7):e28387. PubMed ID: 32400952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comment on: Toxicity profile of high-dose methotrexate in young children with central nervous system tumors.
    Cohen IJ
    Pediatr Blood Cancer; 2024 Nov; 71(11):e31270. PubMed ID: 39118228
    [No Abstract]   [Full Text] [Related]  

  • 9. Systemic high-dose intravenous methotrexate for central nervous system metastases.
    Lassman AB; Abrey LE; Shah GD; Panageas KS; Begemann M; Malkin MG; Raizer JJ
    J Neurooncol; 2006 Jul; 78(3):255-60. PubMed ID: 16344918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Older age, CNS leukaemic involvement and induction tumour lysis increases the risk of methotrexate (MTX)-induced neurotoxicity in childhood acute lymphoblastic leukaemia/lymphoma: Experience from a tertiary care centre in South India.
    Rupakumar T; Sankar A; Vijayasekharan K; Varikkattu Rajendran P; Chellapan Sojamani G; Rajeswari B; Nair M; Anandarajan R; Dennis D; Thankamony P
    Br J Haematol; 2024 Jul; 205(1):220-228. PubMed ID: 38797523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CNS-directed therapy in young children with T-lineage acute lymphoblastic leukemia: High-dose methotrexate versus cranial irradiation.
    Nathan PC; Maze R; Spiegler B; Greenberg ML; Weitzman S; Hitzler JK
    Pediatr Blood Cancer; 2004 Jan; 42(1):24-9. PubMed ID: 14752790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of prehydration on the clearance and toxicity of high-dose methotrexate for pediatric patients.
    Karremann M; Sauerbier J; Meier C; Vetter C; Schneider H; Buchholz B; Mildenberger S; Dürken M
    Leuk Lymphoma; 2014 Dec; 55(12):2874-8. PubMed ID: 24576168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis.
    Fang Y; Su N; Ma S; Cai J; Zhong L; Li W; Huang H; Li Z; Huang H; Xia Y; Liu P; Guo L; Li Z; Wu Y; Tian X; Wang J; Zhang Y; Cai Q
    Ann Hematol; 2022 Mar; 101(3):595-605. PubMed ID: 34985557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate.
    Rask C; Albertioni F; Schrøder H; Peterson C
    Pediatr Hematol Oncol; 1996; 13(4):359-67. PubMed ID: 8837142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of plasma methotrexate, neutropenia, hepatic dysfunction, nausea/vomiting and oral mucositis in children with cancer.
    Cheng KK
    Eur J Cancer Care (Engl); 2008 May; 17(3):306-11. PubMed ID: 18419635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urine volume to hydration volume ratio is associated with pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma.
    Isono T; Hira D; Morikochi A; Fukami T; Ueshima S; Nozaki K; Terada T; Morita SY
    Pharmacol Res Perspect; 2021 Dec; 9(6):e00883. PubMed ID: 34664791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
    Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
    Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.
    Maiguma T; Hayashi Y; Ueshima S; Kaji H; Egawa T; Chayama K; Morishima T; Kitamura Y; Sendo T; Gomita Y; Teshima D
    Int J Clin Pharmacol Ther; 2008 Nov; 46(11):584-90. PubMed ID: 19000557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of thymidylate synthase polymorphisms on toxicities associated with high-dose methotrexate in childhood acute lymphoblastic leukemia.
    Al-Sheikh A; Yousef AM; Alshamaseen D; Farhad R
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):379-385. PubMed ID: 33170323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboxypeptidase G2 rescue after high-dose methotrexate.
    DeAngelis LM; Tong WP; Lin S; Fleisher M; Bertino JR
    J Clin Oncol; 1996 Jul; 14(7):2145-9. PubMed ID: 8683248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.